Key result
Transcriptional modulator JDP2 emerges as a potential prognostic marker and therapeutic target for post-MI heart failure.
Why the study?
Heart failure and atrial fibrillation causes and mechanisms are incompletely understood, and current therapies cannot stop disease progression.
Does Jun dimerization protein 2 (JDP2) contribute to the development of heart failure and atrial fibrillation?
Does Jun dimerization protein 2 (JDP2) contribute to the development of heart failure and atrial fibrillation?
JDP2 is a novel transcriptional modulator that may serve as a prognostic marker and therapeutic target for heart failure and atrial fibrillation based on preclinical evidence.
Does not yet alter post-MI management; leaves open JDP2 validation as prognostic marker or target in prospective studies.
Heart failure (HF) and atrial fibrillation (AF) are two major life-threatening diseases worldwide. Causes and mechanisms are incompletely understood, yet current therapies are unable to stop disease progression. In this review, we focus on the contribution of the transcriptional modulator, Jun dimerization protein 2 (JDP2), and on HF and AF development. In recent years, JDP2 has been identified as a potential prognostic marker for HF development after myocardial infarction. This close correlation to the disease development suggests that JDP2 may be involved in initiation and progression of HF as well as in cardiac dysfunction. Although no studies have been done in humans yet, studies on genetically modified mice impressively show involvement of JDP2 in HF and AF, making it an interesting therapeutic target.
No takes yet. Share an insight, caveat, or question.
Euler et al. (2021) conducted a review in Heart failure and atrial fibrillation. JDP2 (Jun dimerization protein 2) was evaluated. JDP2 is a transcriptional modulator identified as a potential prognostic marker for heart failure development after myocardial infarction, representing a promising therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: